AbbVie Strikes $63 Billion Deal for Botox Maker Allergan, U.S. Set to Delay China Tariffs, Protecting Burls

Rebecca Spalding, Bloomberg News Biotech Reporter, and Max Nisen, Bloomberg Opinion Health Care Columnist, break down AbbVie agreeing to pay $63 billion for rival drugmaker Allergan, the latest huge merger in a pharmaceutical sector rapidly being reshaped by deals. Sarah McGregor, Bloomberg News U.S. Economic Policy Team Leader, explains that U.S. is willing to suspend the next round of tariffs on an additional $300 billion of Chinese imports while Beijing and Washington prepare to resume trade negotiations. Connor Browne, Portfolio Manager at Thornburg Investments, talks about stocks in his long/short strategy. Businessweek Editor Joel Weber and Bloomberg News Venture Capital ReporterSarah McBride discuss how using technology can be used to protect parts of Redwood trees. And we Drive to the Close with Joe Barrato, CEO at Arrow Investment Advisors.

Hosts: Carol Massar and Jason Kelly.  Producer: Paul Brennan 

See omnystudio.com/listener for privacy information.